Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.47) by 41.3 percent. This is a 25.29 percent increase over losses of $(0.87) per share from the same period last year.